Medova, Michaela (2016). Tepotinib. Selective MET receptor tyrosine kinase inhibitor, Treatment of lung and liver cancers. Drugs of the Future, 41(11), p. 659. Prous Science 10.1358/dof.2016.041.11.2555984
Full text not available from this repository.Item Type: |
Journal Article (Original Article) |
|---|---|
Division/Institute: |
04 Faculty of Medicine > Department of Haematology, Oncology, Infectious Diseases, Laboratory Medicine and Hospital Pharmacy (DOLS) > Clinic of Radiation Oncology |
UniBE Contributor: |
Medova, Michaela |
Subjects: |
600 Technology > 610 Medicine & health |
ISSN: |
0377-8282 |
Publisher: |
Prous Science |
Language: |
English |
Submitter: |
Beatrice Scheidegger |
Date Deposited: |
03 May 2017 15:24 |
Last Modified: |
05 Dec 2022 15:02 |
Publisher DOI: |
10.1358/dof.2016.041.11.2555984 |
URI: |
https://boris.unibe.ch/id/eprint/94789 |
Actions (login required)
 |
Edit item |